Phase II Trial of HisproUK, Low-Dose tPA Dual Therapy for Ischemic Stroke Initiated
The dual-therapy regimen will be compared to high-dose tPA monotherapy, the standard of care, in patients with distal blood clots post-stroke.
LYS-SAF302 Granted IND Clearance for Phase II-III Trial in MPS IIIA
Previously, in a 5-year phase I-II trial, the rAAV vector serotype rh.10 showed promising safety data.
Fred Lublin, MD: The Primary Care Partnership in Multiple Sclerosis
The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke about the relationship between primary care and specialists.
Diagnosing Migraine, Knowing the Basics
Berk spoke to the important partnership between primary care and specialists in neurology.
Trial Data Models Patient Transport for Suspected Stroke with Large-Vessel Occlusion
For ischemic stroke with suspected large-vessel occlusion, regional centralization of care is estimated to result in the best outcomes.
Hand-Me-Downs: The CIDP Therapeutic Landscape
The director of the electromyography laboratory and a professor of neurology at Cedars-Sinai spoke about the treatment options for CIDP.
The Importance of Identifying Responders in Migraine
With the pending decision on 2 more CGRP agents, the need for biomarkers to identify responders has never been greater.
Peter Goadbsy, MD, PhD, DSc: Differentiating Between CGRPs, Synthesizing the Gepants
Goadsby spoke about differentiating between the foursome of preventive therapies soon to be available to physicians.
Fred Lublin, MD: The Need for Biomarkers in Multiple Sclerosis
The Saunders Family Professor of Neurology and the director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center discussed the need for biomarkers in MS.
A Bright Horizon for Migraine Treatments
Thomas Berk, MD, discussed the current therapeutic landscape of migraine, emphasizing the importance of conversing with each patient to identify an individualized approach.
Cautious Optimism Amid Excitement About CGRP Inhibitors for Migraine Prevention
David Dodick, MD, a neurologist at Mayo Clinic who’s been involved with multiple trials of headache medicines, provided further insight into the medication class.
Stroke Identified as Independent Risk Factor for All-Cause Dementia
A meta-analysis revealed a history of stroke increases dementia risk by around 70%, and recent strokes more than doubled the risk.
Robert J. Fox on Ibudilast in Progressive Multiple Sclerosis
The neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic touched on the therapy’s performance in a phase II clinical trial.
Dextroamphetamine Fails to Improve Post-Stroke Motor Recovery
Despite supportive preclinical data, no evidence showed that dextroamphetamine in combination with physiotherapy leads to improvement in post-stroke recovery.
Getting the Most Out of CIDP Treatments, Despite Lack of Breakthroughs
Jeffrey Allen, MD, spoke about the breakthrough barrier in CIDP and the importance of the guidelines for diagnosis.
Ibudilast Slows Brain Atrophy in Progressive Multiple Sclerosis Trial
The small molecule slowed atrophy by roughly 2.5 mL less brain-tissue loss compared to placebo.
Nusinersen Shown to Benefit Patients with Spinal Muscular Atrophy at Later Stage
Results provide Class IV evidence that nusinersen is safe and efficient on motor symptoms in patients older than 7 months of age.
Hospital Readmission Rates Decline for Patients Post-Stroke
Data suggest that nationally representative readmission metrics be used to benchmark hospital’s performance.
Vertigo With an Effective Treatment But an Unknown Cause?
Perceptive neurologists have discovered a new type of vertigo. So far, the cause is unknown, though treatment seems to be effective.
Current CIDP Treatment Options and Remaining Targets With Jeffrey Allen
What are the best available options for patients with CIDP, and what is still missing?
Asking, Educating and Clarifying Parkinson Patient Care Goals with Kathrin LaFaver, MD
The Director of the Movement Disorders Clinic at the University of Louisville emphasized the importance of knowing each patient, where they’re coming from and their goals.
Novel Nusinersen Delivery System Shows Success for Patients with SMA
A subcutaneous intrathecal catheter delivery system has proven safe and tolerable in a preliminary investigation in patients with SMA.
Improvements in ALS Treatment Point to a Positive Future
The director of the ALS Clinic at Massachusetts General Hospital pointed to the robust pipeline and meaningful gains in knowledge about the disease as reason to be hopeful.
The Therapeutic Landscape of Parkinson, a Multi-System Disease
The director of the Movement Disorders Clinic at University of Louisville spoke about current therapies available for patients but stressed that they often don’t address the non-motor features.
Christina Szperka on the State of Care in Pediatric Migraine
The director of the Pediatric Headache Program at the Children’s Hospital of Philadelphia said that for these patients, there are still many questions without answers.
Peter J. Goadsby, MD, PhD, DSc: Migraine Prevention Post-Approval of Erenumab
How did erenumab's approval by the FDA change the landscape of migraine treatment?
Valbenazine for Tardive Dyskinesia Improves AIMS Score With Continued Treatment
The VMAT2 inhibitor showed improvements through 48 weeks, though after halting therapy, some loss of improvement was observed.
DTHR-ALZ Receives Breakthrough Device Designation for Alzheimer Disease
If granted approval, DTHR-ALZ would be the first non-pharmacological prescription treatment to mitigate agitation and depression associated with Alzheimer disease.
Could CGRP Inhibitors be Effective in Pediatric Migraine?
The director of the Pediatric Headache Program at Children’s Hospital of Philadelphia spoke about the potential for CGRP inhibitors to find use in pediatric patients.
Opicapone Maintains Efficacy in Parkinson Disease in Open-Label Extension
The COMT inhibitor resulted in 65-minute and 39-minute decreases in mean off time for patients who switched from placebo and entacapone, respectively.
